StocksMedium•5 November 2026•
1 min read
Scinai Immunotherapeutics Reports Revenue Growth for First Nine Months of 2026
Key Facts
1Scinai Immunotherapeutics reported financial results for the nine months ended September 30, 2026, highlighting expansion in its CDMO business.
2An October agreement advanced the U.S. customer program to approximately $5.1 million in committed base services.
Scinai Immunotherapeutics reported financial results for the nine months ended September 30, 2026, highlighting an expansion in its contract development and manufacturing organization (CDMO) business. The company stated in a PR Newswire release that an agreement signed in October advanced a U.S. customer program to approximately $5.1 million in committed base services.
SCNI closed at $0.4488 on November 4, 2026. These results follow the company's efforts to scale its manufacturing capabilities, which have contributed to the growth of its revenue base and long-term service commitments.